Nanosizing: a formulation approach for poorly-water-soluble compounds

Adachi, 1992, Tumoricidal activity of Kupffer cells augmented by anticancer drugs, Life Sci., 51, 177, 10.1016/0024-3205(92)90073-X

Akers, 2002, Excipient–drug interactions in parenteral formulations, J. Pharm. Sci., 91, 2283, 10.1002/jps.10154

Allen, 1997, Liposomes: opportunities in drug delivery, Drugs, 54, 8, 10.2165/00003495-199700544-00004

Aungst, 2000, Intestinal permeation enhancers, J. Pharm. Sci., 89, 429, 10.1002/(SICI)1520-6017(200004)89:4<429::AID-JPS1>3.0.CO;2-J

Benet, 1999, Intestinal MDR transport proteins and P-450 enzymes as barriers to oral drug delivery, J. Control. Release, 62, 25, 10.1016/S0168-3659(99)00034-6

Bittner, B., Mountfield, R.J., 2002. Intravenous administration of poorly soluble new drug entities in early drug discovery: The potential impact of formulation on pharmacokinetic parameters. Cur. Opin. Drug Discovery and Dev., 59–71.

Breitenbach, 2002, Melt extrusion: from process to drug delivery technology, EJPB, 54, 107

Byrn, 1995, Pharmaceutical solids: a strategic approach to regulatory considerations, Pharm. Res., 12, 945, 10.1023/A:1016241927429

Cooper, 2000, Nanoparticles in drug delivery

Couvreur, 1990, Nanoparticles as microcarriers for anticancer drugs, Adv. Drug Deliv. Rev., 5, 209, 10.1016/0169-409X(90)90017-M

Dressman, 1998, Dissolution testing as a prognostic tool for oral drug adsorption: immediate release dosage forms, Pharm. Res., 15, 11, 10.1023/A:1011984216775

Floyd, 1999, Top ten considerations in the development of parenteral emulsions, Pharm. Sci. Tech., 4, 134, 10.1016/S1461-5347(99)00141-8

Gref, 1994, Biodegradable long-circulating polymeric nanospheres, Science, 263, 1600, 10.1126/science.8128245

Gregoriades, 1995, Engineering liposomes for drug delivery: progress and problems, TIBTECH, 13, 527, 10.1016/S0167-7799(00)89017-4

Hobbs, 1998, Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment, Proc. Natl. Acad. Sci., 95, 4607, 10.1073/pnas.95.8.4607

Horter, 2001, Influence of physicochemical properties on dissolution of drugs in the gastrointestinal tract, Adv. Drug Deliv. Rev., 46, 75, 10.1016/S0169-409X(00)00130-7

Illum, 1982, Blood clearance and organ disposition of intravenously administered colloidal particles. Effect of particle size, nature, and shape, Int. J. Pharm., 2, 135, 10.1016/0378-5173(82)90113-2

Jain, 1996, Delivery of molecular medicine to solid tumors, Science, 271, 1079, 10.1126/science.271.5252.1079

Juliano, 1988, Factors affecting the clearance kinetics and tissue distribution of liposomes, microspheres and emulsions, Adv. Drug Deliv. Rev., 2, 31, 10.1016/0169-409X(88)90004-X

Kibbe, 2000

Kong, 2000, Hypothermia enables tumor-specific nanoparticle delivery: effect of particle size, Cancer Res., 60, 4440

Kusuhara, 1998, The role of p-glycoprotein and canalicular multispecific organic anion transporter in the hepatobiliary excretion of drugs, J. Pharm. Sci., 87, 1025, 10.1021/js970100b

Lawrence, 2000, Microemulsion-based media as novel drug delivery systems, Adv. Drug Deliv. Rev., 45, 89, 10.1016/S0169-409X(00)00103-4

Lee, 2000, Bioadhesive-based dosage forms: the next generation, J. Pharm. Sci., 89, 850, 10.1002/1520-6017(200007)89:7<850::AID-JPS2>3.0.CO;2-G

Leuner, 2000, Improving drug solubility for oral delivery using solid dispersions, Eur. J. Pharm. Biopharm., 50, 47, 10.1016/S0939-6411(00)00076-X

Lipinski, 1997, Experimental and computational approaches to estimate solubility and permeability in drug discovery and development setting, Adv. Drug Deliv. Rev., 23, 3, 10.1016/S0169-409X(96)00423-1

Lipinski, 2001, Avoiding investment in doomed drugs, is poor solubility an industry wide problem?, Curr. Drug Dis., 17

Lipinski, 2002, Poor aqueous solubility—an industry wide problem in drug discovery, Am. Pharm. Rev., 5, 82

Lipper, 1999, E pluribus product, Mod. Drug Dis., 2, 55

Liversidge, G.G., Cundy, K.C., Bishop, J.F., Czekai, D.A., 1992. Surface modified drug nanoparticles. U.S. Patent 5,145,684.

Liversidge, 1995, Particle size reduction for improvement of oral bioavailability of hydrophobic drugs: I. Absolute oral bioavailability of nanocrystalline danazol in beagle dogs, Int. J. Pharm., 125, 91, 10.1016/0378-5173(95)00122-Y

Liversidge, 1995, Drug particle size reduction for decreasing gastric irritancy and enhancing absorption of naproxen in rats, Int. J. Pharm., 125, 309, 10.1016/0378-5173(95)00148-C

Liu, 2000, Pharmacokinetic and hepatic disposition of Bis[1-ethoxycarbonyl)propyl]5-acetylamino-2,3,6-triiodoisophthalate in rats and isolated perfused rat livers, Drug Metab. Dispos., 28, 731

Loftsson, 1996, Pharmaceutical applications of cyclodextrins, J. Pharm. Sci., 85, 1017, 10.1021/js950534b

Loper, 1999, Poorly soluble compounds: vehicle selection and solubilization

Martin, 1982, Tumoricidal effect of macrophages exposed to adriamycin in vivo or in vitro, Cancer Res., 42, 3851

Merisko-Liversidge, 1996, Formulation and antitumor activity evaluation of nanocrystalline suspensions of poorly soluble anticancer drugs, Pharm. Res., 13, 272, 10.1023/A:1016051316815

Moghimi, 2001, Long-circulating and target-specific nanoparticles: theory to practice, Pharmacol. Rev., 53, 283

Muller, 2001, Nanosuspensions as particulate drug formulations in therapy: rationale for development and what we can expect for the future, Adv. Drug Deliv. Rev., 47, 3, 10.1016/S0169-409X(00)00118-6

Na, 1999, Physical stability of ethyl diazoate nanocrystalline suspension in steam sterilization, Pharm. Res., 16, 569, 10.1023/A:1018883431970

Nakano, 2000, Places of emulsions in drug delivery, Adv. Drug Deliv. Rev., 45, 1, 10.1016/S0169-409X(00)00096-X

Neal, 1998, Modification of copolymers poloxamer 407 and poloxamine 908 can affect the physical and biological properties of surface modified nanospheres, Pharm. Res., 15, 318, 10.1023/A:1011987206722

Nouchi, 1998, Early phase tumor accumulation of macromolecules: a great difference in clearance rate between tumor and normal tissue, Jpn. J. Cancer Res., 89, 307, 10.1111/j.1349-7006.1998.tb00563.x

Pace, 1999, Novel injectable formulations of insoluble drugs, Pharm. Tech., 23, 116

Papisov, 1998, Theoretical considerations of RES-avoiding liposomes: molecular mechanics and chemistry of liposome interactions, Adv. Drug Deliv. Rev., 32, 119, 10.1016/S0169-409X(97)00135-X

Rogers, 2001, A comprehensive review: solution-based particle formation of pharmaceutical powders by supercritical or compressed fluid CO2 and cryogenic spray-freezing technologies, Drug Dev. Ind. Pharm., 27, 1003, 10.1081/DDC-100108363

Schott, 1955, Colloidal dispersions, 252

Serajuddin, 1999, Solid dispersion of poorly water-soluble drugs: early promises, subsequent problems, and recent breakthroughs, J. Pharm. Sci., 88, 1058, 10.1021/js980403l

Soma, 2000, Investigation of the role of macrophages on the cytotoxicity of doxorubicin and doxorubicin-loaded nanoparticles on M5076 cells in vitro, J. Control. Release, 68, 283, 10.1016/S0168-3659(00)00269-8

Stella, 1997, Cyclodextrins: their future in drug formulation and delivery, Pharm. Res., 14, 556, 10.1023/A:1012136608249

Stolnik, 1995, Long circulating microparticulate drug carriers, Adv. Drug Deliv. Rev., 16, 195, 10.1016/0169-409X(95)00025-3

Tom, 1991, Particle formation with supercritical fluids—a review, J. Aersol Sci., 22, 555, 10.1016/0021-8502(91)90013-8

Toster, 1990, Modification of the body distribution of poly(methylmethacrylate) nanoparticles in rats by coating with surfactants, Int. J. Pharm., 61, 85, 10.1016/0378-5173(90)90047-8

Veber, 2002, Molecular properties that influence oral bioavailability of drug candidates, J. Med. Chem., 45, 2615, 10.1021/jm020017n

Venkatesh, 2000, Role of the development scientist in compound lead selection and optimization, J. Pharm. Sci., 89, 145, 10.1002/(SICI)1520-6017(200002)89:2<145::AID-JPS2>3.0.CO;2-6

Wiedmann, 1997, Nebulization of nanocrystals: production of a respirable solid-in-liquid-in-air colloidal dispersion, Pharm. Res., 14, 112, 10.1023/A:1012024021511

Woodle, 1998, Controlling liposome blood clearance by surface-grafted polymers, Adv. Drug Deliv. Rev., 32, 139, 10.1016/S0169-409X(97)00136-1

Zheng, 1997, Sterile filtration of nanocrystal drug formulations, Drug Dev. Ind. Pharm., 23, 1087, 10.3109/03639049709150497